EFFECT OF LONG-TERM ENDURACIN MONOTHERAPY ON CLINICOBIOCHEMICAL CHARACTERISTICS OF PATIENTS WITH ISCHEMIC-HEART-DISEASE

13 patients aged 39 to 60 years with coronary atherosclerosis confirme d at selective coronary angiography combined with primary hyperlipidem ia (phenotypes 2a and 2b) received enduracin in a dose 1500 mg/day. As a result of the treatment total cholesterol (TC) and LDL cholesterol lowered by 10.3 and 13.1%, respectively, whereas HDL cholesterol rose by 15.2%. Half of the patients demonstrated activation of hepatic tran saminases, but discontinuation of the drug was not necessary. In 3 out of 4 patients after 2 years of enduracin treatment stabilization of a therosclerosis was observed. Thus, long-term enduracin is able to inhi bit progression of atherosclerosis in coronary heart disease patients.